Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 12/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30916753 | 1.00 | AOC2 (0.51) | AOC2KDM4EALDH1A1MAOALMNA | |
| SCHEMBL24057984 | 1.00 | AOC2 (0.51) | AOC2KDM4EALDH1A1MAOALMNA | |
| SCHEMBL24058217 | 0.92 | KMT2A (0.53) | AOC2ALDH1A1MAOALMNASMN1; SMN2 | |
| SCHEMBL24025501 | 0.92 | KMT2A (0.53) | AOC2ALDH1A1MAOALMNASMN1; SMN2 | |
| SCHEMBL24025477 | 0.90 | AOC2 (0.58) | AOC2ALDH1A1MAOAMAOB | |
| SCHEMBL24025660 | 0.90 | AOC2 (0.51) | AOC2MAOAMAOB | |
| SCHEMBL24058359 | 0.90 | AOC2 (0.58) | AOC2ALDH1A1MAOAMAOB | |
| SCHEMBL24025499 | 0.89 | AOC2 (0.52) | AOC2MAOAMAOB | |
| SCHEMBL23779179 | 0.89 | AOC2 (0.52) | AOC2MAOAMAOB | |
| SCHEMBL23779177 | 0.89 | AOC2 (0.52) | AOC2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873599-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-27 | — | — | EP | disclosed |
| US-20210353608-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353608-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ARSA, SULT1A1, SULT2A1 | AOC2 4191/4885KDM4E 3461/4885ALDH1A1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.